Zacharon Pharmaceuticals Inc.
Glycan-targeted therapeutic platform for developing drugs that modulate carbohydrate structures on proteins and lipids
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Latest Form D
- $33K, Apr 2012
- Total capital
- $6.3M
- Federal grants
- $5.8M
- 16 awards · 2005–2012
- 16× sector median 1 award
- Private capital raised
- $548K
- 3 Form D · last Apr 2012
- 175 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 9 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Development of a Small Molecule Therapy for Metachromatic Leukodystrophy$296K
- Private capital raisedForm D · SEC · 3rd filing$33K
- Federal grantHealth and Human S · Phase I · Development of a Novel Biomarker for Mucopolysaccharidosis I, II, and VI$336K
- Private capital raisedForm D · SEC · 2nd filing$15K
- Federal grantHealth and Human S · Phase I · A Novel Small Molecule Therapy for Tay-Sachs and Sandhoff Diseases$343K
- Private capital raisedForm D · SEC · 1st filing$500K
- Federal grantHealth and Human S · Phase II · Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$999K
Show 12 earlier federal awards
- Federal grantHealth and Human S · Phase II · Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$1.0M
- Federal grantHealth and Human S · Phase I · Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$340K
- Federal grantHealth and Human S · Phase I · Structure-activity relationship study of an inhibitor of tumor metastasis$188K
- Federal grantHealth and Human S · Phase I · Inhibitors of Heparan Sulfate Biosynthesis and Cancer$196K
- Federal grantHealth and Human S · Phase I · Chondroitin Sulfate Inhibitor Screen for Neural-Regeneration Drugs$115K
- Federal grantHealth and Human S · Phase I · Development of a cell-based screen for inhibitors of ganglioside biosynthesis$100K
- Federal grantHealth and Human S · R21 · Development of cell-based assays for discovery of GIcNAc-TV inhibitors.$125K
- Federal grantHealth and Human S · Phase II · Development of Novel Inhibitors of Ganglioside Biosynthesis$697K
- Federal grantHealth and Human S · Phase II · Development of Novel Inhibitors of Ganglioside Biosynthesis$106K
- Federal grantHealth and Human S · Phase II · Development of Novel Inhibitors of Ganglioside Biosynthesis$175K
- Federal grantHealth and Human S · Phase II · Development of Novel Inhibitors of Ganglioside Biosynthesis$652K
- Federal grantHealth and Human S · R21 · Cell-Based Screen-Inhibitors of Mucin-Type O-Linked(RMI)$125K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
57months
from Zacharon Pharmaceuticals Inc.’s first federal award to its first private round.
- First federal award · Sep 2005
- Health and Human S · $125K
- First Form D · Jun 2010
- $500K · 1st Form D
- Awards before first raise
- 13 awards
An association in public records, not a cause or a prediction.
Founders and team
From SEC Form D filings- Charles A. GlassDirectorNamed in SEC Form D filings
- Court B. TurnerExecutive Officer, DirectorNamed in SEC Form D filings
- Douglas J. CownsExecutive OfficerNamed in SEC Form D filings
- Douglas J. DownsExecutive OfficerNamed in SEC Form D filings
- Jay B. LichterDirectorNamed in SEC Form D filings
- Robin M. JackmanExecutive Officer, DirectorNamed in SEC Form D filings
Show all 7 people
- Timothy B. ScottDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 9- PendingQuantification Of Non-reducing End Glycan Residual CompoundsUSPTOApplication PCTUS2013061914
- PendingGlycosaminoglycan InhibitorsUSPTOApplication PCTUS2010062247
- PendingO-linked Glycan Biosynthesis ModulatorsUSPTOApplication PCTUS2010030574
Show all 9 patent records
- Quantification Of Non-reducing End Glycan Residual CompoundsApplication PCTUS2013061914Pending
- Glycosaminoglycan InhibitorsApplication PCTUS2010062247Pending
- O-linked Glycan Biosynthesis ModulatorsApplication PCTUS2010030574Pending
- N-linked Glycan Biosynthesis ModulatorsApplication PCTUS2010029087Pending
- Ganglioside Biosynthesis ModulatorsApplication PCTUS2010029082Pending
- Detection Of OligosaccharidesApplication PCTUS2009069941Pending
- Polymer End Group DetectionApplication PCTUS2009069946Pending
- Quantification Of Non-reducing End Glycan Residual CompoundsApplication PCTUS2009069944Pending
- Heparan Sulfate InhibitorsApplication PCTUS2009049450Pending
Related companies, and why
- Parnell Pharmaceuticals Holdings LtdSimilar federal contract value in Biotech · null in contracts
- Intervene Immune, Inc.Similar federal contract value in Biotech · null in contracts
- LongRun P.B.C.Similar federal contract value in Biotech · null in contracts
- Foment Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Clovis OncologySimilar federal contract value in Biotech · null in contracts
- Arteriocyte Medical Systems IncSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .